MPMarjan Piponski

Marjan Piponski

*This is an algorithmically generated author record based on publicly available information.

Marjan Piponski has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The usage of salts of chaotropic anions for the development of HPLC method for the simultaneous determination of cisplatin and carboplatin in model mixture

    by Mariana Druchok, Marjan Piponski, Mariana Horyn, Nadiya Zarivna, Liliya Logoyda

    The aim of the work was to develop an RP-HPLC method for the simultaneous determination of extremely polar and non-UV-absorbing chromophore molecules of cisplatin and carboplatin in a model mixture using salts of chaotropic anions, which can be used for single-analyte determination too. Material and methods: HPLC analysis was performed using Agilent 1260 and Shimadzu LC-2050C with diode array detector (DAD). Cisplatin and carboplation (purity ≥99% (HPLC)) were supplied from Sigma-Aldrich Chemicals Co. (St. Louis, MO, USA). Used dosage forms: cisplatin «Ebeve» (0.5 mg/ml, Austria) and carboplatin «Ebeve» (10 mg/ml, Austria). All used reagents were HPLC gradient chromatography quality and purchased from Merck Darmstadt, Germany. Results and discussion: Chaotropic agents enhance retention of basic molecules in acidic mobile phases on reversed-phase chromatographic columns and improve peak shape and symmetry. The chaotropic anions that increase interaction between the basic N-containing analyte and the alkyl chains of reversed-phase ligands, such as C-8 and C-18, are frequently employed to enhance and improve the performance of HPLC methods. The chromatographic analysis of cisplatin and carboplatin presented a unique challenge due to their inorganic structure. The experimentally established optimal chromatographic conditions are: mobile phase - 40 mM KPF6 buffer solution (pH 2.4) and ACN (95:5), chromatographic column - Luna C18 (100 x 4.6 mm 3 µm), column temperature - 30 °C, flow rate - 0.4 ml/min, detection wavelength - 210 nm. Linearity was assessed using five levels of each of the investigated drugs, where concentration varied in the range of 20–100 μg/mL. The proposed HPLC method is green, as confirmed by the most modern metrics for studying greenness (AGREE, MoGAPI, complex MoGAPI, AGSA, CaFRI and CACI). Conclusions. In this work, thorough scientific research was carried out with the presentation of HPLC method development for the simultaneous determination of extremely highly polar molecules cisplatin and carboplatin in a model mixture using salts of chaotropic anions. In addition, two studied drugs were quantified using rapid, simple, cost-effective HPLC method approaches

  • Open Access

    Full green assay of rosuvastatin utilizing sulphophtalein dyes: application to tablet analysis

    by Liudmyla Halka, Tetyana Kucher, Liubomyr Kryskiw, Marjan Piponski, Mariana Horyn, Olha Poliak, Nadiya Zarivna, Liliya Logoyda

    The aim of the work was to develop a «green» and extraction-free spectrophotometric procedure for the assay of rosuvastatin in tablets. The present work describes three new spectrophotometric procedures (A, B and C) that can be utilized for routine quality control of rosuvastatin in laboratories. Materials and methods. Analytical instrumentation: Shimadzu UV-1800 double beam UV-vis spectrophotometer (Japan) with attached UV-Probe ver. 2.62 software, RAD WAG AS 200/C precise analytical balance (Poland). Rosuvastatin calcium (purity ≥98 % (HPLC)) was bought from Sigma-Aldrich Chemicals Co. (St. Louis, MO, USA). Rosuvastatin 10 mg tablets were acquired from a nearby drugstore. All solvents used in this study, including methanol, ethanol, chloroform, acetonitrile and ethyl acetate, were produced by Honeywell and had a purity of 99.9 %. BCG, BCP and BTB were acquired from Sigma-Aldrich Chemicals Co. (USA, St. Louis). All chemicals utilized in the experiment were of analytical purity. Results and discussion. New simple «green» and extraction-free spectrophotometric procedures for assay of rosuvastatin in tablets involve the formation of ion-pair complexes with sulphophtalein dyes (BCG (Method A), BCP (Method B), BTB (Method C)) have been developed. The absorbances of the coloured reaction products were registered at 405 nm (Method A) and 400 nm (Methods B, C). The concentration was linearly proportional to absorbance values in the range of 2.51-20.08 μg/mL (method A), 2.50-24.90 μg/mL (method B) and 2.51-12.56 μg/mL (method C). Estimation of LOD and LOQ parameters were obtained as 0.67 μg/mL and 2.23 μg/mL (Method A), 0.39 μg/mL and 1.32 μg/mL (Method B), 0.30 μg/mL and 1.01 μg/mL (Method C). The stoichiometric ratio of the reactive components of rosuvastatin - BCG, BCP, and BTB corresponded 1: 1. The %RSD values of intra-day and inter-day were obtained less than < 1.5 %, which showed excellent repeatability and RE % data was ≤ 3 %. The effect on the environment of the proposed spectrophotometric procedures and their compliance with the GAC principles were endorsed by the output of AGREE, GAPI, and AES metrics tools. The values of these three «green» metrics show that the proposed spectrophotometric procedures had a low environmental impact compared with the reported ones. Conclusions. The developed fast, simple and cost-effective methods A, B, and C can be used for routine analysis of rosuvastatin in tablets


  • Open Access

    Development of the spectrophotometric method for the determination of meldonium in capsules by using alizarine

    by Mariana Horyn, Marjan Piponski, Olha Poliak, Nataliia Shulyak, Marta Sulyma, Liliya Logoyda

    The aim of the work was to develop a simple, rapid, economic spectrophotometric method for the determination of meldonium in capsules based on the reaction with alizarin. Materials and methods. Analytical equipment: double-beam UV-visible spectrophotometer Shimadzu UV 1800 (Japan), a pair of 1 cm matched quartz cells, software UV-Probe 2.62, laboratory electronic balance RAD WAG AS 200/C, pH-meter И-160МИ. Pharmacopoeial standard sample (CRS) of meldonium dihydrate (Sigma-Aldrich, (≥ 98 %, HPLC)), alizarin (Synbias), capsules Metamax (Darnytsia) 250 mg, Vasopro (Farmak) 500 mg, Mildronate (Grindex) 500 mg, dimethylformamide (“Honeywell Riedel-de Haen”). Results and discussion. A spectrophotometric method for determining meldonium in capsules by reaction with alizarine has been developed. The absorption maximum of the formed complex in dimethylformamide was at a wavelength of 517 nm. Stoichiometric ratios of reactive components «meldonium- alizarin» were 1:1. Validation of the developed analytical method for the determination of meldonium in medicines was carried out in accordance with the requirements of the SPhU. The optimal conditions for performing the quantitative determination of meldonium have been established: concentration of alizarin solution – 0.8 %, volume 0.8 % alizarin solution – 0.5 ml, heating time – 20 min, temperature – 95+/- 2 °C. Linearity has been in the concentration range of 0.0402- 0.1073 mg/mL, the limit of detection - 2.84 μg/mL, and the limit of quantification – 8.59 μg/mL. The eco-friendliness of the developed analytical method was carried out using the analytical eco-scale, AGREE, and GAPI methods. Conclusions. The developed method can be used as an arbitration method for the routine analysis of meldonium capsules Метою роботи була розробка простої, швидкої та економічно доступної спектрофотометричної методики визначення мельдонію в капсулах на основі реакції з алізарином. Матеріали та методи. Аналітичне обладнання: двопроменевий УФ-видимий спектрофотометр Shimadzu UV 1800 (Японія), пара кварцевих кювет з товщиною 1 см, програмне забезпечення UV-Probe 2.62, ваги лабораторні електронні RAD WAG AS 200/C, pH–метр И-160МИ. Фармакопейний стандартний зразок (ФСЗ) мельдонію дигідрату (Sigma-Aldrich, (≥ 98 %, ВЕРХ)), алізарин (Синбіас), капсули «Метамакс» 250 мг (Дарниця, серія NS № 20222 ), «Вазопро» 500 мг (Фармак, серія № 20321, 50821, 10222, 20222, 30222 ), «Мілдронат» 500 мг (Grindex, серія № 4750321) Результати та обговорення. Розроблено спектрофотометричну методику визначення мельдонію в капсулах за реакцією з алізарином. Максимум поглинання утвореного комплексу в диметилформаміді спостерігали за довжини хвилі 517 нм. Стехіометричні співвідношення реагуючих компонентів «мельдоній – алізарин» 1:1. Валідацію розробленої аналітичної методики визначення мельдонію в капсулах проводили відповідно до вимог ДФУ. Встановлено оптимальні умови проведення кількісного визначення мельдонію: концентрація розчину алізарину - 0.8 %, об’єм 0.8 % розчину алізарину – 0.5 мл, час нагрівання - 20 хв, температура нагрівання – (95+/-2) °C. Лінійність спостерігалась в діапазоні концентрацій 0.0402-0.1073 мг/мл, МВ – 2.84 мкг/мл, МКВ – 8.59 мкг/мл. Екологічність розробленої аналітичної методики розраховували методами аналітичної еко – шкали, AGREE та GAPI.Висновки. Розроблена методика може бути використана як арбітражна для рутинного аналізу капсул мельдонію

  • Open Access

    Development of the spectrophotometric method for the determination of rosuvastatin in tablets by using bromophenol blue

    by Liudmyla Halka, Tetyana Kucher, Liubomyr Kryskiw, Marjan Piponsk, Iryna Furdela, Tetyana Uglyar, Olha Poliak, Liliya Logoyda

    The aim of the work was to develop a spectrophotometric method for the determination of rosuvastatin in tablets based on the reaction with BPB in compliance with the principles of «green» chemistry. Material and methods. Analytical equipment: two-beam UV-visible spectrophotometer Shimadzu model -UV 1800 (Japan), software UV-Probe 2.62, electronic laboratory balance RAD WAG AS 200/C. The following APIs, dosage forms, reagents and solvents were used in work: pharmacopoeial standard sample (CRS) of rosuvastatin calcium (Sigma-Aldrich, (≥ 98 %, HPLC)), BCG (Sigma-Aldrich, (≥ 98 %, HPLC)), "Rosuvastatin" tablets 10 mg, 15 mg, 20 mg, methanol (Honeywell, (≥ 99.9 %, GC)), ethanol (Honeywell, (≥ 99.9 %, GC)), chloroform (Honeywell, (≥ 99.9 %, GC)), acetonitrile (Honeywell, (≥ 99.9 %, GC)), and ethyl acetate (Honeywell, (≥ 99.7 %, GC)). Results and discussion. A spectrophotometric method for determining rosuvastatin by reaction with BPB in an acetonitrile solution using the absorption maximum at a wavelength of 595 nm has been developed. Stoichiometric ratios of reactive components were established, which were 1:1. The developed method for the quantitative determination of rosuvastatin was validated following the requirements of the SPhU. The analytical method was linear in the 7.99-23.97 μmol/L concentration range. The LOD and LOQ values were calculated to be 0.77 µmol/L and 2.36 µmol/L. According to the «greenness» pictogram of the analytical method using the AGREE method, the score was 0.77, indicating that the proposed spectrophotometric method for determining rosuvastatin was developed in compliance with the principles of «green» chemistry. Conclusions. An eco-friendly spectrophotometric method has been developed to quantitatively determine rosuvastatin in tablets based on the reaction with BPB. The appropriate sulfophthalein dye (BPB) and its concentration (4.00 x 10-4), the optimal eco-friendly solvent (acetonitrile), and the appropriate wavelength (595 nm) were chosen, and the sensitivity of the reaction was calculated. The analytical method was validated, and its possibility for use in the pharmaceutical analysis was shown


  • Open Access

    Application of salts of chaotropic anions in the development of hplc methods for the determination of meldonium in dosage forms

    by Mariana Horyn, Marjan Piponski, Tetiana Zaremba, Tetyana Kucher, Svetlana Krstevska Balkanov, Tanja Bakovska Stoimenova, Dmytro Korobko, Nataliia Potikha, Liubomyr Kryskiw, Liliya Logoyda

    The aim of the work was to create an approach for the development of HPLC methods for the determination of meldonium in dosage forms with the usage of salts of chaotropic anions in mobile phases. Material and methods. Analytical equipment: Shimadzu UPLC system LC-40 PDA; Shimadzu Nexera-i LC-2040C 3D-Plus, controlled by software Lab Solution version 5.97, electronic laboratory balance RAD WAG AS 200/C, pH-meter I-160MI. Meldonium dihydrate (purity 99.3 %) was purchased from Sigma-Aldrich (Switzerland), and Vasopro capsules 500 mg were purchased from a local pharmacy. Chromatographic conditions: Agilent Zorbax C-18 SB 150 mm x 4.6 mm 3.5 μm column was used (Agilent Technologies, USA). Mobile phases: 1) 0.25 % KPF6 w/v – 0.1 % v/v 85 %H3PO4 95 % – 5 % ACN, 2) 0.3 % bis-(trifluoromethane)sulfonimide lithium salt 97 % w/v – 0.1 %v/v 85 % H3PO4 80 % – 20 % acetonitrile. Flow rate - 1mL/min, T=32 °C, detection UV=at 4 channels - 190 nm, 195 nm, 200 nm, 205 nm. Results and discussion. We have proposed two approaches using two different salts of chaotropic anions - potassium hexafluorophosphate and bis-(trifluoromethane)sulfonimide lithium salt – for the HPLC method development. The chaotropic effects of these anions toward meldonium strongly influenced the analyte migratory behaviour. Both mobile phases involved, in addition to the use of a chaotrope, also the use of acetonitrile and pH adjustment with 0.1 % v/v 85 % H3PO4 solution. The detection wavelength (190 nm, 195 nm, 200 nm, 205 nm) was selected experimentally. The results were obtained for 8 concepts. Parameters of the chromatographic system confirm the conclusions and results of this investigation for the influence of chaotropic salts on N-containing molecules in an acidic pH medium, by increasing their retentivity and improving peak shape and uniformity homogeneity, even on the column without end-capping and base-deactivating. Validation of the analytical method was carried out following the requirements of SPhU. Conclusions. HPLC methods for the determination of meldonium in dosage forms have been developed, using positive impacts of chaotropic salts on the molecules containing N-atoms in their molecule on their retentions and peak symmetries on the chromatogram. The validation of the analytical methods showed their suitability for pharmaceutical analysis


  • Open Access

    Chiral Monolithic Silica-Based HPLC Columns for Enantiomeric Separation and Determination: Functionalization of Chiral Selector and Recognition of Selector-Selectand Interaction

    by Mufarreh Asmari, Xiaoyu Wang, Natalia Casado, Marjan Piponski, Sergiy Kovalenko, Liliya Logoyda, Rasha Sayed Hanafi, Sami El Deeb

    This review draws attention to the use of chiral monolithic silica HPLC columns for the enantiomeric separation and determination of chiral compounds. Properties and advantages of monolithic silica HPLC columns are also highlighted in comparison to conventional particle-packed, fused-core, and sub-2-µm HPLC columns. Nano-LC capillary monolithic silica columns as well as polymeric-based and hybrid-based monolithic columns are also demonstrated to show good enantioresolution abilities. Methods for introducing the chiral selector into the monolithic silica column in the form of mobile phase additive, by encapsulation and surface coating, or by covalent functionalization are described. The application of molecular modeling methods to elucidate the selector–selectand interaction is discussed. An application for enantiomeric impurity determination is also considered.


  • Open Access

    Development of a Novel, Fast, Simple HPLC Method for Determination of Atorvastatin and its Impurities in Tablets

    by Nataliia Shulyak, Marjan Piponski, Sergiy Kovalenko, Tanja Bakovska Stoimenova, Trajan Balkanov, Hussein I. El-Subbagh, Iryna Drapak, Joy Oluwatobiloba Omotosho, Liliya Logoyda

    Our main target and concept was to develop a method for the determination of the most prescribed antilipemic drug, atorvastatin, together with its related substances, with a single sample preparation and during a single chromatographic run, in the shortest possible period of time, with the lowest possible mobile phase consumption. A new rapid, simple chromatographic method for the determination of atorvastatin and its main specified impurities was developed, using different chromatographic columns. With this new concept of a mobile phase and a powerful core–shell, or a superficially porous silica-based column, satisfactory results for targeted parameters, such as critical peak resolution, run time length, and column backpressure, were achieved. The analysis is performed within a run duration of less than 15 min, which is about six times shorter than the official European Pharmacopoeia method. The chromatogram performances suggests that the method limit of quantification (LOQ) can be about 7 times lower, and the limit of detection (LOD) about 20 times lower, using an injection volume of only 2 µl. This was confirmed by the performed method validation in accordance with the International Conference on Harmonization (ICH) guideline for the validation of analytical procedures Q2(R1), where the selectivity, linearity, accuracy, precision, limit of quantification, and limit of detection were tested and confirmed.


  • Open Access

    Development and validation of a fast, simple, cost-effective and robust HPLC method for lisinopril determination in solid pharmaceutical dosage forms

    by Tanja Bakovska Stoimenova, Marjan Piponski, Gordana Trendovska Serafimovska, Marina Stefova

    A fast, simple, cost-effective and robust chromatographic method was developed and validated for determination of the antihypertensive drug lisinopril dihydrate in tablets under routine operational conditions, without ion-pair reagents, high column temperatures and an acidic mobile phase. Taking into consideration all four different pKa values of lisinopril, the separation was optimized using the C18 column (end-capped, 150 mm × 4.6 mm 5 µm) and a mobile phase composed of methanol and ammonium (or potassium) dihydrogen phosphate buffer (pH 7.2) with a flow rate of 1.1 ml/min, UV detection at 214 nm and a temperature of 40 °C. These optimized conditions led to the production of a single and symmetrical peak for lisinopril. This mobile phase is suitable for different HPLC columns, which makes it appropriate for industrial quality control laboratories. The developed method was validated, showing excellent validation results and the possibility to be implemented for the determination of lisinopril in combined dosage forms with other active substances.